Benzinga | Jan 10, 2022 08:05AM EST

Cardiff Oncology To Host Conference Call And Webcast To Discuss Updated Data From Lead Clinical Program In KRAS-mutated Metastatic Colorectal Cancer Being Presented At 2022 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that it will be hosting a conference call and webcast to discuss updated data from its lead clinical program in KRAS-mutated metastatic colorectal cancer on Tuesday, January 18, 2022, at 5:00 PM ET.